Print Page | Sign In | Join Today
News & Press: Company News

CEL-SCI Granted European Patent on Multikine

Friday, November 20, 2015  
Share |
CEL-SCI Corporation has been granted a European patent on Multikine (Leukocyte Interleukin, Injection), its investigational Phase 3 cancer immunotherapy. The patent, number EP 1 753 452 B, is entitled: A METHOD FOR ALTERING THE CD4/CD8 RATIO AND THE MONONUCLEAR CELLULAR INFILTRATE INTO A TUMOR.

The patent is important because it recites a mechanism of action of Multikine by which Multikine changes the type of T cells that enter the tumor microenvironment. This change results in the tumor becoming “visible” to the immune system, resulting in a robust and sustainable anti-tumor immune response.

Positive results with Multikine in earlier clinical studies confirmed by pathology were published. An ongoing Phase 3 clinical trial against advanced primary (not yet treated) head and neck cancer is progressing rapidly. The study is ongoing in 24 countries and so far has enrolled over 600 patients. In October 2015 the clinical research organization that runs the study added $2 million to its co-development investment in the Phase 3 study. Their investment of $12 million will only be repaid from a successful drug.

Our Premium Partners

Sign up for our newsletter
800 E. Leigh St.  |  Richmond, Va 23219-1534  |  PH: 804.643.6360  |  Email Us
Stay Connected